cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Intellia Therapeutics Inc
109 own
35 watching
Current Price
$43.15
$0.71
(1.67%)
logo-ntla
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,304.77M
52-Week High
52-Week High
104.87
52-Week Low
52-Week Low
32.435
Average Volume
Average Volume
1.21M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization3,304.77M
icon52-Week High104.87
icon52-Week Low32.435
iconAverage Volume1.21M
iconDividend Yield--
iconP/E Ratio--
What does the Intellia Therapeutics Inc do?
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Intellia Therapeutics Inc make?
News & Events about Intellia Therapeutics Inc.
Zolmax
11days ago
JMP Securities downgraded shares of Intellia Therapeutics (NASDAQ:NTLA Get Rating) from an outperform rating to a market perform rating in a research report sent to investors on Thursday morning, Marketbeat.com reports. Several other brokerages have also recently issued reports on NTLA. Wells Fargo...
Zolmax
19days ago
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA Get Rating) have been given an average rating of Moderate Buy by the twenty research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold ...
Globe Newswire
22days ago
Innovation Passport provides entry to the U.K.s Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines NTLA-2002 is a single-dose genome editing therapeutic candidate designed to prevent angioedema attacks in ...
Globe Newswire
28days ago
Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platformSubmit IND application in mid-2023 as part of a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) ...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies,announced today the pricing of an underwritten public offering of 6...
Frequently Asked Questions
Frequently Asked Questions
What is Intellia Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Intellia Therapeutics Inc shares?
plus_minus_icon
How can I buy Intellia Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Intellia Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Intellia Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Intellia Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Intellia Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Intellia Therapeutics Inc?
plus_minus_icon
What percentage is Intellia Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Intellia Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$43.15
$0.71
(1.67%)
logo-ntla
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00